Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update
Mesenchymal stromal cells (MSCs) are characterized by an extraordinary capacity to modulate the phenotype and functional properties of various immune cells that play an essential role in the pathogenesis of inflammatory disorders. Thus, MSCs efficiently impair the phagocytic and antigen-presenting c...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2021.637725/full |
id |
doaj-1e1d2d3802e6401c9a6a73cd97374963 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Luise Müller Antje Tunger Antje Tunger Manja Wobus Malte von Bonin Malte von Bonin Malte von Bonin Russell Towers Martin Bornhäuser Martin Bornhäuser Martin Bornhäuser Martin Bornhäuser Francesco Dazzi Rebekka Wehner Rebekka Wehner Rebekka Wehner Marc Schmitz Marc Schmitz Marc Schmitz Marc Schmitz |
spellingShingle |
Luise Müller Antje Tunger Antje Tunger Manja Wobus Malte von Bonin Malte von Bonin Malte von Bonin Russell Towers Martin Bornhäuser Martin Bornhäuser Martin Bornhäuser Martin Bornhäuser Francesco Dazzi Rebekka Wehner Rebekka Wehner Rebekka Wehner Marc Schmitz Marc Schmitz Marc Schmitz Marc Schmitz Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update Frontiers in Cell and Developmental Biology mesenchymal stromal cells immunomodulation macrophages dendritic cells T cells |
author_facet |
Luise Müller Antje Tunger Antje Tunger Manja Wobus Malte von Bonin Malte von Bonin Malte von Bonin Russell Towers Martin Bornhäuser Martin Bornhäuser Martin Bornhäuser Martin Bornhäuser Francesco Dazzi Rebekka Wehner Rebekka Wehner Rebekka Wehner Marc Schmitz Marc Schmitz Marc Schmitz Marc Schmitz |
author_sort |
Luise Müller |
title |
Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update |
title_short |
Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update |
title_full |
Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update |
title_fullStr |
Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update |
title_full_unstemmed |
Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update |
title_sort |
immunomodulatory properties of mesenchymal stromal cells: an update |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Cell and Developmental Biology |
issn |
2296-634X |
publishDate |
2021-02-01 |
description |
Mesenchymal stromal cells (MSCs) are characterized by an extraordinary capacity to modulate the phenotype and functional properties of various immune cells that play an essential role in the pathogenesis of inflammatory disorders. Thus, MSCs efficiently impair the phagocytic and antigen-presenting capacity of monocytes/macrophages and promote the expression of immunosuppressive molecules such as interleukin (IL)-10 and programmed cell death 1 ligand 1 by these cells. They also effectively inhibit the maturation of dendritic cells and their ability to produce proinflammatory cytokines and to stimulate potent T-cell responses. Furthermore, MSCs inhibit the generation and proinflammatory properties of CD4+ T helper (Th)1 and Th17 cells, while they promote the proliferation of regulatory T cells and their inhibitory capabilities. MSCs also impair the expansion, cytokine secretion, and cytotoxic activity of proinflammatory CD8+ T cells. Moreover, MSCs inhibit the differentiation, proliferation, and antibody secretion of B cells, and foster the generation of IL-10-producing regulatory B cells. Various cell membrane-associated and soluble molecules essentially contribute to these MSC-mediated effects on important cellular components of innate and adaptive immunity. Due to their immunosuppressive properties, MSCs have emerged as promising tools for the treatment of inflammatory disorders such as acute graft-versus-host disease, graft rejection in patients undergoing organ/cell transplantation, and autoimmune diseases. |
topic |
mesenchymal stromal cells immunomodulation macrophages dendritic cells T cells |
url |
https://www.frontiersin.org/articles/10.3389/fcell.2021.637725/full |
work_keys_str_mv |
AT luisemuller immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT antjetunger immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT antjetunger immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT manjawobus immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT maltevonbonin immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT maltevonbonin immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT maltevonbonin immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT russelltowers immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT martinbornhauser immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT martinbornhauser immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT martinbornhauser immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT martinbornhauser immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT francescodazzi immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT rebekkawehner immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT rebekkawehner immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT rebekkawehner immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT marcschmitz immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT marcschmitz immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT marcschmitz immunomodulatorypropertiesofmesenchymalstromalcellsanupdate AT marcschmitz immunomodulatorypropertiesofmesenchymalstromalcellsanupdate |
_version_ |
1724277936458039296 |
spelling |
doaj-1e1d2d3802e6401c9a6a73cd973749632021-02-09T05:30:24ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2021-02-01910.3389/fcell.2021.637725637725Immunomodulatory Properties of Mesenchymal Stromal Cells: An UpdateLuise Müller0Antje Tunger1Antje Tunger2Manja Wobus3Malte von Bonin4Malte von Bonin5Malte von Bonin6Russell Towers7Martin Bornhäuser8Martin Bornhäuser9Martin Bornhäuser10Martin Bornhäuser11Francesco Dazzi12Rebekka Wehner13Rebekka Wehner14Rebekka Wehner15Marc Schmitz16Marc Schmitz17Marc Schmitz18Marc Schmitz19Institute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, GermanyInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyDepartment of Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyDepartment of Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyGerman Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyDepartment of Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, GermanyGerman Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, GermanyCenter for Regenerative Therapies Dresden (CRTD), TU Dresden, Dresden, GermanySchool of Cancer and Pharmacological Sciences and KHP Cancer Research UK Centre, King’s College London, London, United KingdomInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyGerman Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, GermanyInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyGerman Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, GermanyCenter for Regenerative Therapies Dresden (CRTD), TU Dresden, Dresden, GermanyMesenchymal stromal cells (MSCs) are characterized by an extraordinary capacity to modulate the phenotype and functional properties of various immune cells that play an essential role in the pathogenesis of inflammatory disorders. Thus, MSCs efficiently impair the phagocytic and antigen-presenting capacity of monocytes/macrophages and promote the expression of immunosuppressive molecules such as interleukin (IL)-10 and programmed cell death 1 ligand 1 by these cells. They also effectively inhibit the maturation of dendritic cells and their ability to produce proinflammatory cytokines and to stimulate potent T-cell responses. Furthermore, MSCs inhibit the generation and proinflammatory properties of CD4+ T helper (Th)1 and Th17 cells, while they promote the proliferation of regulatory T cells and their inhibitory capabilities. MSCs also impair the expansion, cytokine secretion, and cytotoxic activity of proinflammatory CD8+ T cells. Moreover, MSCs inhibit the differentiation, proliferation, and antibody secretion of B cells, and foster the generation of IL-10-producing regulatory B cells. Various cell membrane-associated and soluble molecules essentially contribute to these MSC-mediated effects on important cellular components of innate and adaptive immunity. Due to their immunosuppressive properties, MSCs have emerged as promising tools for the treatment of inflammatory disorders such as acute graft-versus-host disease, graft rejection in patients undergoing organ/cell transplantation, and autoimmune diseases.https://www.frontiersin.org/articles/10.3389/fcell.2021.637725/fullmesenchymal stromal cellsimmunomodulationmacrophagesdendritic cellsT cells |